Skip to main content

Table 3 Patterns of DPP-4i use, N = 105

From: Dipeptidyl Peptidase-4 inhibitors use in type II diabetic patients in a tertiary hospital

Parameters/characteristicsn (%)
Types of DPP-4i
 Vildagliptin39 (37.1)
 Sitagliptin32 (30.5)
 Saxagliptin26 (24.8)
 Linagliptin8 (7.6)
Duration of use (months) a29.7 ± 19.8
 < 2446 (43.8)
 ≥ 2459 (56.2)
Fixed-dose combination (FDC) tablets
 Vildagliptin/Metformin27 (25.7)
 Sitagliptin/Metformin21 (20.0)
 Saxagliptin/Metformin18 (17.1)
Metformin
 FDC66 (62.9)
 Add on29 (27.6)
 Total95 (90.5)
Other concurrent antidiabetics
 Insulin59 (56.2)
 Gliclazide IR/MR27 (25.7)
 Glibenclamide1 (1.0)
 Acarbose3 (2.9)
 None28 (26.7)
Types of insulin therapy
 Basal bolus28 (26.7)
 Premixed15 (14.3)
 Bolus only15 (14.3)
 Basal only1 (1.0)
Adherence
 Good58 (55.2)
 Poor13 (12.4)
 Not documented34 (32.4)
  1. aContinuous variable reported as mean ± SD